Visual images of prescription drug benefits in direct-to-consumer television advertisements

Sullivan, Helen W.; O’Donoghue, Amie C.; Lynch, Molly; Johnson, Mihaela; Davis, Christine; Amoozegar, Jacqueline; Rupert, Douglas

doi:10.1016/j.pec.2021.02.024

Cited by 6 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, our results largely suggest that this was not the case: neither length of the ISI nor the presence of the brief summary was related to perceived risk on its own. Some research found that direct information about the likelihood of risks and benefits (via quantitative information or comparative claims) affects perceptions, but that the presentation format of risk information does not 15,24–32 . Others have speculated that the lack of findings related to risk perceptions may be due to inattention or lack of time spent on the material 33,34 .…”

Section: Discussionmentioning

confidence: 99%

“…Some research found that direct information about the likelihood of risks and benefits (via quantitative information or comparative claims) affects perceptions, but that the presentation format of risk information does not. 15,[24][25][26][27][28][29][30][31][32] Others have speculated that the lack of findings related to risk perceptions may be due to inattention or lack of time spent on the material. 33,34 Based on the findings from the selfreported and eye-tracking data showing participants were paying attention to the risk information, we can infer that the lack of effects on this variable are not due to lack of attention.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Attention to risk information in direct‐to‐consumer prescription drug print ads: An eye‐tracking study

Aikin

Sullivan

Caporaso

et al. 2022

Pharmacoepidemiology and Drug

Self Cite

View full text Add to dashboard Cite

Purpose: FDA regulations state print ads for prescription drugs must provide a true statement of information "in brief summary" describing "side effects, contraindications and effectiveness." To fulfill these requirements, these ads typically display risk information both as important safety information (ISI) on the "main" ad page with the product claims and on a separate "brief summary" page. The ISI can be lengthy and may repeat brief summary content. Methods:The authors tested two versions of the ISI (short versus long) and the presence or absence of a brief summary in direct-to-consumer prescription drug print ads for two medical conditions: overactive bladder (N = 181) and rheumatoid arthritis (N = 179). Attention was measured with eye-tracking and self-report methods. Risk retention and perceptions were self-reported.Results: Participants spent more time viewing ads with a long ISI or a brief summary and in some instances, recalled more risks. The combination of a long ISI and a brief summary did not increase or decrease attention to or retention of risk information. Conclusion:A long ISI and a brief summary may perform similar functions.

show abstract

Section: Discussionmentioning

confidence: 99%